Live Breaking News & Updates on Stoke Therapeutics Inc

Stay updated with breaking news from Stoke therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that. ....

United States , United Kingdom , Stoke Therapeutics Inc , Augmentation Of Nuclear Gene Output , Goldman Sachs , Stoke Therapeutics , Annual Global Healthcare Conference , Targeted Augmentation , Nuclear Gene Output ,

Stoke Therapeutics (NASDAQ:STOK) Shares Down 4%

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s stock price dropped 4% during mid-day trading on Tuesday . The stock traded as low as $13.75 and last traded at $13.83. Approximately 166,733 shares traded hands during trading, a decline of 82% from the average daily volume of 922,683 shares. The stock had previously closed at […] ....

United States , Jonathan Allan , Cantor Fitzgerald , Stoke Therapeutics Inc , Dorsey Whitney Trust , Canaccord Genuity Group , York Mellon Corp , Jpmorgan Chase Co , Securities Exchange Commission , Needham Company , Pricet Rowe Associates Inc , Board Of Administration Florida Retirement System , Stoke Therapeutics Company Profile , Stoke Therapeutics , Get Free Report , Genuity Group , Exchange Commission , General Counsel Jonathan Allan , New York Mellon Corp , Financial Markets , Florida Retirement System , Whitney Trust , Stoke Therapeutics Daily ,

Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.2%

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s stock price was up 7.2% during trading on Wednesday . The company traded as high as $16.49 and last traded at $16.46. Approximately 277,244 shares changed hands during trading, a decline of 70% from the average daily volume of 932,838 shares. The stock had previously closed at […] ....

United States , Stephenj Tulipano , Needham Company , Vanguard Group Inc , Securities Exchange Commission , Stoke Therapeutics Company Profile , Capital Partners , Cantor Fitzgerald , Stoke Therapeutics Inc , Redmile Group , Jpmorgan Chase Co , Stoke Therapeutics , Get Free Report , Exchange Commission , Stoke Therapeutics Daily ,

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Stoke Therapeutics Inc ,

Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight s, Encephalopathy Pipeline Insight 2024 report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It. ....

United States , Las Vegas , Yash Bhardwaj , Knoop Biosciences , Neurocrine Biosciences , Axcella Health , Biosciences Inc , Company Name Drug , Xenon Pharmaceuticals , Longboard Pharmaceuticals , Stoke Therapeutics Inc , Encephalopathy Xenon Pharmaceuticals , Delveinsight Business Research , Xenon Pharmaceuticals Drug , Pipeline Insight , Encephalopathy Pipeline Report , Precision Medicines , State Biosciences Inc , Promising Encephalopathy Pipeline Therapies , Ornithine Phenylacetate , Fenfluramine Hydrochloride , Standard Medical Therapy , Randomized Controlled Trial , Treat Hepatic , Therapeutics Inc , Open Label Study ,